Parenteral Estrogen versus Combined Androgen Deprivation in the Treatment of Metastatic Prostatic Cancer - Scandinavian Prostatic Cancer Group (SPCG) Study No. 5

@article{Hedlund2002ParenteralEV,
  title={Parenteral Estrogen versus Combined Androgen Deprivation in the Treatment of Metastatic Prostatic Cancer - Scandinavian Prostatic Cancer Group (SPCG) Study No. 5},
  author={P. O. Hedlund and M. Ala-opas and E. Brekkan and J. Damber and L. Damber and I. Hagerman and S. Haukaas and P. Henriksson and P. Iversen and {\AA}. Pousette and F. Rasmussen and J. Salo and S. Vaage and E. Varenhorst},
  journal={Scandinavian Journal of Urology and Nephrology},
  year={2002},
  volume={36},
  pages={405 - 413}
}
Objective : In the mid-1980s, interest in parenteral estrogen therapy for prostate cancer was renewed when it was found that it influenced liver metabolism only marginally and had very few cardiovascular side-effects. In this study high-dose polyestradiol phosphate (PEP; Estradurin ® ) was compared to combined androgen deprivation (CAD) for the treatment of patients with metastatic prostate cancer. The aim of the study was to compare anticancer efficacy and adverse events, especially… Expand
Endocrine treatment of prostate cancer
  • T. Tammela
  • Medicine
  • The Journal of Steroid Biochemistry and Molecular Biology
  • 2004
Recent progress in hormonal therapy for advanced prostate cancer
Transdermal estradiol in castrate and chemotherapy resistant prostate cancer
  • M. Stein, S. Goodin, +6 authors R. DiPaola
  • Medicine
  • Medical science monitor : international medical journal of experimental and clinical research
  • 2012
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 33 REFERENCES
Leuprolide versus diethylstilbestrol for metastatic prostate cancer.
  • Medicine
  • The New England journal of medicine
  • 1984
Estrogens in the treatment of prostate cancer.
The Importance of Prognostic Factors in Advanced Prostate Cancer
...
1
2
3
4
...